Showing results (151-160 of 259) with videos related to
Sort By:
Pageof 26
The Patient|November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.Investigational New Drugs|March 9, 2023
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 studyJames Chih-Hsin Yang, Wu-Chou Su, Chao-Hua Chiu, et al.Journal of the National Cancer Institute|April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2014
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancerJih-Hsiang Lee, Yu-Lin Lin, Wei-Hsun Hsu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 15, 2022
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in AsiaTetsuya Mitsudomi, Daniel Tan, James Chih-Hsin Yang, et al.European Journal of Cancer (Oxford, England : 1990)|September 18, 2023
Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health systemChing-Yao Yang, Jin-Yuan Shih, Wei-Yu Liao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker AnalysesTony S K Mok, Sang-We Kim, Yi-Long Wu, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 26, 2020
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in TaiwanYuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, et al.Pageof 26